✦ LIBER ✦

Pharmacokinetic–pharmacodynamic (PK–PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs

✍ Scribed by Papich, Mark G.

Book ID: 121686392
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 303 KB
Volume: 171
Category: Article
ISSN: 0378-1135
DOI: 10.1016/j.vetmic.2013.12.021

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WS04 The population PK/PD approach for a

WS04 The population PK/PD approach for a rational use of anti-infective drugs to minimize resistance

✍ P. L. TOUTAIN; P. LEES 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB

Use of a pharmacokinetic/pharmacodynamic

Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib

✍ J. M. GIRAUDEL; J. N. KING; E. C. JEUNESSE; P. LEES; P.-L. TOUTAIN 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

The application of mechanism-based PK/PD

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

✍ Benjamin Wu; Amita Joshi; Song Ren; Chee Ng 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB

muM17 is an anti-mouse CD11a monoclonal antibody (mAb) developed as a surrogate molecule for assessing potential reproductive toxicities of efalizumab, an anti-human CD11a mAb approved for treatment of chronic moderate to severe plaque psoriasis. This article shows the use of a mechanism-based PK/PD

342 A MOUSE MODEL WITH LONG TERM EXPRESS

342 A MOUSE MODEL WITH LONG TERM EXPRESSION OF HEPATITIS C VIRUS NS3/4A PROTEASE FOR THE PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) STUDY OF HCV PROTEASE INHIBITORS

✍ J. Lin; J. Hong; S. Lim; X. Qin; L. Pan; L. Huang; J. Liu; C. Schaefer; S. Ammon 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

From Target Selection to the Minimum Acc

From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics

✍ Jing Yu; Helene Karcher; Adam L. Feire; Philip J. Lowe 📂 Article 📅 2011 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 600 KB

Evaluation of the pharmacokinetics–pharm

Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection

✍ Olanrewaju O. Okusanya; Brian T. Tsuji; Jurgen B. Bülitta; Alan Forrest; Cathari 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 631 KB